Arecor Therapeutics operates in formulation technology and development of insulin and other biologic medicines. ThisBusinessmodel gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability to convert expertise,Assetsor …
Fusion Antibodies operates in pre-clinical antibody discovery, engineering andSupplyservices for therapeutic and diagnostic developers. This business model gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability to …
Genedrive operates in molecular diagnostic tests and point-of-care genetic testing systems. ThisBusinessmodel gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability to convert expertise,Assetsor customer relationships into …
• Investors are watching new launches, product mix and returns on research spending.
Kromek Group operates in radiation detection, advanced imaging and chemical, biological, radiological and nuclear detection technology. ThisBusinessmodel gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability to …
Kooth operates in digital mental-health services delivered through online platforms, including services for young people and adults. ThisBusinessmodel gives the company exposure to specialised demand, but it also means investors need to distinguish addressable-market potential fromRevenuethat is already contracted or repeatable. The company’s ability …
GSK Plc (LSE:GSK) shares rose 0.66% to 1,902.5p today, with attention on the pharmaceutical group's latest quarterly update and its continuing shift towards specialty medicines. The move follows a third-quarter report in which management reaffirmed its 2026 guidance.
Haleon Plc (LSE:HLN) shares rose 1.45% to 342.5p today, as the market continued to digest the consumer health group's third-quarter trading statement. The update included a lower organic growth outlook for 2026 alongside a further £500m share buyback.
Convatec Group Plc (LSE:CTEC) shares rose 0.71% to 255.8p today. The modest gain comes after first-half 2026 results that showed 5.0% organic growth excluding InnovaMatrix, a higherInterim Dividendand a new $200 million share buyback.
AstraZeneca Plc (LSE:AZN) shares rose 0.98% to 14,162.0p today, supported by continued attention on its latest quarterly update and a deep pipeline of late-stage medicines.